Impact of Fibroblast Growth Factor 23 (FGF-23) and Serum Phosphate on Allograft Function and Mortality in Kidney Allograft Recipients

Impact of FGF-23 and Serum Phosphate on Allograft Function and Mortality in Kidney Allograft Recipients

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00903578

Enrollment

200

Registered

2009-05-18

Start date

2009-05-31

Completion date

2015-01-31

Last updated

2009-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Transplantation

Keywords

FGF-23, vitamin D, phosphate, allograft dysfunction, mortality

Brief summary

The present study will examine whether serum FGF-23 and serum phosphate at baseline of kidney transplant recipients can predict progression of allograft dysfunction at 3 years and all-cause mortality at 5 years.

Interventions

None listed

Study design

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* at least one year post-transplantation * no more than 10% increase in serum creatinine for the past 3 months

Exclusion criteria

* refuse to participate in the study * any acute illnesses

Design outcomes

Primary

Measure	Time frame
Progression of allograft dysfunction and all-cause Mortality	3 and 5 years

Secondary

Measure	Time frame
Relationship of FGF-23 and 25-OH-D, 1-25-OH-D, PTH, calcium, phosphate, urine phosphate and eGFR	1 year

Countries

Thailand

Outcome results